Oxidative Stress Promotes Doxorubicin‐Induced Pgp and BCRP Expression in Colon Cancer Cells Under Hypoxic Conditions

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Journal of Cellular Biochemistry

• Publication date

  2017-07-01

• Fields of study

  Biology, Medicine, Environmental Science

• Identifiers
  DOI 10.1002/jcb.25890PMID 28106284
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Involvement of Notch‐1 in Resistance to Regorafenib in Colon Cancer Cells

  2016cited by this paper
• Prediction of Cancer Drug Resistance and Implications for Personalized Medicine

  2015cited by this paper
• MicroRNA‐195 Chemosensitizes Colon Cancer Cells to the Chemotherapeutic Drug Doxorubicin by Targeting the First Binding Site of BCL2L2 mRNA

  2015cited by this paper
• Increased Oxidative Stress as a Selective Anticancer Therapy

  2015cited by this paper
• Chemotherapy triggers HIF-1–dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype

  2015cited by this paper
• Chemoresistance to doxorubicin induces epithelial-mesenchymal transition via upregulation of transforming growth factor β signaling in HCT116 colon cancer cells

  2015cited by this paper
• Targeting extracellular ROS signaling of tumor cells.

  2014cited by this paper
• Is redox signaling a feasible target for overcoming multidrug resistance in cancer chemotherapy?

  2014cited by this paper
• HIF-1α Inhibition Reverses Multidrug Resistance in Colon Cancer Cells via Downregulation of MDR1/P-Glycoprotein

  2014cited by this paper
• Aberrant expression of redox protein Ape1 in colon cancer stem cells

  2014cited by this paper
• Targeting antioxidants for cancer therapy.

  2014cited by this paper
• Cancer statistics, 2014

  2014cited by this paper
• Downregulating hypoxia‐inducible factor‐2α improves the efficacy of doxorubicin in the treatment of hepatocellular carcinoma

  2012cited by this paper
• Prediction of Altered 3′- UTR miRNA-Binding Sites from RNA-Seq Data: The Swine Leukocyte Antigen Complex (SLA) as a Model Region

  2012cited by this paper
• Doxorubicin blocks proliferation of cancer cells through proteolytic activation of CREB3L1

  2012cited by this paper
• Increased JNK1 Signaling Pathway Is Responsible for ABCG2-Mediated Multidrug Resistance in Human Colon Cancer

  2012cited by this paper
• Reactive Oxygen Species Reduction is a Key Underlying Mechanism of Drug Resistance in Cancer Chemotherapy

  2012cited by this paper
• Toxicity Assessment of Iron Oxide Nanoparticles in Zebrafish (Danio rerio) Early Life Stages

  2012cited by this paper
• Impact of APE1/Ref-1 Redox Inhibition on Pancreatic Tumor Growth

  2011cited by this paper
• Oxidative stress and ERK1/2 phosphorylation as predictors of outcome in hepatocellular carcinoma patients treated with sorafenib plus octreotide LAR

  2011cited by this paper
• Review: Combination therapy in high-risk stage II or stage III colon cancer: current practice and future prospects

  2010cited by this paper
• Chemotherapeutic drug-induced ABCG2 promoter demethylation as a novel mechanism of acquired multidrug resistance.

  2009cited by this paper
• Treatment of resistant human colon cancer xenografts by a fluoxetine-doxorubicin combination enhances therapeutic responses comparable to an aggressive bevacizumab regimen.

  2009cited by this paper
• Overcoming multidrug resistance in cancer: An update on research of natural products

  2009cited by this paper
• Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?

  2009cited by this paper
• Doxorubicin activates FOXO3a to induce the expression of multidrug resistance gene ABCB1 (MDR1) in K562 leukemic cells

  2008cited by this paper
• Hypoxia-induced resistance to anticancer drugs is associated with decreased senescence and requires hypoxia-inducible factor-1 activity

  2008cited by this paper
• RhoA Silencing Reverts the Resistance to Doxorubicin in Human Colon Cancer Cells

  2008cited by this paper
• Post-transcriptional Regulation of P-Glycoprotein Expression in Cancer Cell Lines

  2007cited by this paper
• Reversal of P-glycoprotein-mediated multidrug resistance in cancer cells by the c-Jun NH2-terminal kinase.

  2006cited by this paper
• Chemoresistance in solid tumours.

  2006cited by this paper
• HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia.

  2006cited by this paper
• Treatment of advanced colorectal cancer with doxorubicin combined with two potential multidrug-resistance-reversing agents: high-dose oral tamoxifen and dexverapamil

  2005cited by this paper
• Proteomics and Cr(VI) exposure: exploring new biomarkers in humans

  2005cited by this paper
• Nitric oxide reverts the resistance to doxorubicin in human colon cancer cells by inhibiting the drug efflux.

  2005cited by this paper
• Breast cancer resistance protein (BCRP/MXR/ABCG2) in acute myeloid leukemia: discordance between expression and function

  2004cited by this paper
• Hypoxia-Mediated Down-Regulation of Bid and Bax in Tumors Occurs via Hypoxia-Inducible Factor 1-Dependent and -Independent Mechanisms and Contributes to Drug Resistance

  2004cited by this paper
• Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein.

  2003cited by this paper
• 5-Fluorouracil: mechanisms of action and clinical strategies

  2003cited by this paper
• Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene.

  2002cited by this paper
• The apurinic/apyrimidinic endonuclease activity of Ape1/Ref-1 contributes to human glioma cell resistance to alkylating agents and is elevated by oxidative stress.

  2002cited by this paper
• Cancer statistics

  1989cited by this paper

• Cancer-on-a-chip for precision cancer medicine

  2025cites this paper
• Model for Predicting Serious Hematological Adverse Events in Individuals With Ovarian Cancer Receiving Poly (Adenosine Diphosphate Ribose) Polymerase Inhibitor Treatment: Prospective Cohort Study

  2025cites this paper
• SUMOylation involved in malignant progression of multiple tumors and SENP5 may improve the chemotherapy sensitivity of hypoxic tumors

  2025cites this paper
• SMARCA1 regulates PARP1-dependent ABC transporters expression and mediates doxorubicin resistance in triple-negative breast cancer

  2025cites this paper
• Regulation of Intestinal Butyrate Transporters by Oxidative and Inflammatory Status

  2025cites this paper
• Chrysosplenetin acts as a homeostasis stabilizer with dual-function in shattering Plasmodium berghei K173 resistance to artemisinin driven by both ABC transporters and heme-ROS/GSH axis

  2025cites this paper
• Advances in Doxorubicin Chemotherapy: Emerging Polymeric Nanocarriers for Drug Loading and Delivery

  2025cites this paper
• Self-oxygenating GMZ@HA nanocarriers enhance doxorubicin cytotoxicity in hypoxic breast cancer

  2025cites this paper
• APX2009 sensitizes hypoxic breast cancer cells to doxorubicin by increasing its accumulation and caspase-3/7-mediated apoptosis

  2024cites this paper
• Research progress in tumor angiogenesis and drug resistance in breast cancer

  2024cites this paper
• Role of HIF-1α in the Responses of Tumors to Radiotherapy and Chemotherapy

  2024cites this paper
• Hypoxia-Inducible Factor-Dependent and Independent Mechanisms Underlying Chemoresistance of Hypoxic Cancer Cells

  2024cites this paper
• Metformin inhibits OCTN1- and OCTN2-mediated hepatic accumulation of doxorubicin and alleviates its hepatotoxicity in mice.

  2024cites this paper
• The APE1/REF-1 and the hallmarks of cancer

  2024cites this paper
• Prognostic modelling of colorectal cancer based on oxidative stress-related genes

  2023cites this paper
• Targeting breast cancer resistance protein (BCRP/ABCG2) in cancer

  2023cites this paper
• Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions

  2023cites this paper
• The Molecular Mechanisms of Oleanane Aldehyde-β-enone Cytotoxicity against Doxorubicin-Resistant Cancer Cells

  2023cites this paper
• Breast Cancer Chemoresistance: Insights into the Regulatory Role of lncRNA

  2023cites this paper
• Inhibition of multiple uptake transporters in cardiomyocytes/mitochondria alleviates doxorubicin-induced cardiotoxicity.

  2023cites this paper
• Saponins and their derivatives: potential candidates to alleviate anthracycline-induced cardiotoxicity and multidrug resistance.

  2022cites this paper
• Mesenchymal stromal/stem cells and their exosomes application in the treatment of intervertebral disc disease: A promising frontier.

  2022cites this paper
• Oxidative stress‐mediated up‐regulation of ABC transporters in lung cancer cells

  2022cites this paper
• Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape

  2022cites this paper
• Characteristics of the cancer stem cell niche and therapeutic strategies

  2022cites this paper
• Heparin and Heparin-Based Drug Delivery Systems: Pleiotropic Molecular Effects at Multiple Drug Resistance of Osteosarcoma and Immune Cells

  2022cites this paper
• Implication of ABC transporters in non-proliferative diseases.

  2022cites this paper
• Hypoxia-Inducible Factor-1: A Novel Therapeutic Target for the Management of Cancer, Drug Resistance, and Cancer-Related Pain

  2022cites this paper
• Effects of kefir on doxorubicin-induced multidrug resistance in human colorectal cancer cells

  2021cites this paper
• Advances in understanding the role of P-gp in doxorubicin resistance: molecular pathways, therapeutic strategies, and prospects.

  2021cites this paper
• Normoxic Tumour Extracellular Vesicles Modulate the Response of Hypoxic Cancer and Stromal Cells to Doxorubicin In Vitro

  2020cites this paper
• Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance.

  2020cites this paper
• p5RHH nanoparticle-mediated delivery of AXL siRNA inhibits metastasis of ovarian and uterine cancer cells in mouse xenografts

  2019cites this paper
• Gaseous signaling molecules and their application in resistant cancer treatment: from invisible to visible.

  2019cites this paper
• Phospholipid-Free Small Unilamellar Vesicles for Drug Targeting to Cells in the Liver.

  2019cites this paper
• The mechanism and tumor inhibitory study of Lagopsis supine ethanol extract on colorectal cancer in nude mice

  2019cites this paper
• Development of precision medicine approaches based on inter-individual variability of BCRP/ABCG2

  2019cites this paper
• Altered Gene expression of ABC transporters, nuclear receptors and oxidative stress signaling in zebrafish embryos exposed to CdTe quantum dots.

  2019cites this paper
• Therapeutic Inhibition of the Receptor Tyrosine Kinase AXL Improves Sensitivity to Platinum and Taxane in Ovarian Cancer

  2018cites this paper
• Co-administration of genistein with doxorubicin-loaded polypeptide nanoparticles weakens the metastasis of malignant prostate cancer by amplifying oxidative damage.

  2018cites this paper
• Transplantation of Hypoxic-Preconditioned Bone Mesenchymal Stem Cells Retards Intervertebral Disc Degeneration via Enhancing Implanted Cell Survival and Migration in Rats

  2018cites this paper
• MDR1 in immunity: friend or foe?

  2018cites this paper
• SQ1274, a novel microtubule inhibitor, inhibits ovarian and uterine cancer cell growth.

  2018cites this paper
• Hypoxic preconditioned bone mesenchymal stem cells ameliorate spinal cord injury in rats via improved survival and migration

  2018cites this paper
• Inhibition of the Receptor Tyrosine Kinase AXL Restores Paclitaxel Chemosensitivity in Uterine Serous Cancer

  2017cites this paper
• Visfatin mediates doxorubicin resistance in human colorectal cancer cells via up regulation of multidrug resistance 1 (MDR1)

  2017cites this paper
• Effects of initiating time and dosage of Panax notoginseng on mucosal microvascular injury in experimental colitis

  2017cites this paper
• Exploiting the Ref-1-APE1 node in cancer signaling and other diseases: from bench to clinic

  2017cites this paper